Perfiles depacientes diabéticos…
317
72.
tatisticsMethodology, Norwegian Institute of Public
[acceso 16.03.2011].
Disponible
en:
73.
orwegian Institute of Public
0.05.2011]. Disponible en:
/
74.
in diabetic patients treated
tformin. DiabetesMetab Res
Rev22, 477-‐82(2006).
75. Gonzalez-‐Ortiz M,
Guerrero-‐Romero JF,
Violante-‐Ortiz R,
et al.
Efficacy of
glimepiride/metformin combination versus glibenclamide/metformin in patients with
uncontrolled type2diabetesmellitus. JDiabetesComplications23, 376-‐9(2009).
76. NathanDM, Buse JB, DavidsonMB, et al.Management of hyperglycemia in type2diabetes:
Aconsensus algorithmfor the initiationandadjustment of therapy: a consensus statement
from the American Diabetes Association and the European Association for the Study of
Diabetes. DiabetesCare29, 1963-‐72(2006).
77. NathanDM, Buse JB, DavidsonMB, et al.Management of hyperglycemia in type2diabetes:
a consensus algorithm for the initiation and adjustment of therapy: update regarding
thiazolidinediones: a consensus statement from the American Diabetes Association and
theEuropeanAssociation for theStudyofDiabetes. DiabetesCare31, 173-‐5(2008).
78. NathanDM, Buse JB, DavidsonMB, et al. Medical management of hyperglycemia in type 2
diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus
statement of the American Diabetes Association and the European Association for the
StudyofDiabetes. DiabetesCare32, 193-‐203(2009).
79. National Collaborating Centre for Chronic Conditions, editores. Type 2 diabetes: national
clinical guideline formanagement inprimary and secondary care (update). London: Royal
Collegeof Physicians, 2008.
80. Schier JG, Hoffman RS, Nelson LS. Metformin-‐induced acidosis due to a warfarin adverse
drugevent. AnnPharmacother37, 1145(2003).
81. Gomes T, Juurlink DN, Lipscombe LL, et al. Clinical and demographic characteristics of
patients receiving different oral hypoglycemic agents. Pharmacoepidemiol Drug Saf 18,
756-‐60(2009).
82. Fornos JA, Patricia García G, Fernández M, et al. Evaluación del conocimiento, el
cumplimiento y la satisfacción del tratamiento en pacientes diabéticos en la oficina de
farmacia. AvDiabetol 24, 399-‐406(2008).
83.
84.
diabetesmellitus. RevClinEsp208, 437-‐43(2008).
85. UBM Medica. Vademecum de m
rincipios activos, dopaje,
interacciones, equivalencias inter
farmacéuticos de España
[acceso14.12.2011]. Disponibleen:
/
86.
87.
88.
89.
10.01.2012].
Disponible
en:
